Literature DB >> 7672935

Peripheral nerve dysfunction in adult patients with cystic fibrosis.

J I O'Riordan1, J Hayes, M X Fitzgerald, J Redmond.   

Abstract

The prevalence of peripheral nerve dysfunction was assessed in 24 randomly selected adult patients with cystic fibrosis. Median, peroneal and sural nerves were studied. In 15 patients (62%), one or more electrical abnormality were detected. In the median nerve, conduction velocity was slowed in 29% of sensory studies and 12.5% of motor studies; compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes were normal. The CAMP was low in 17% of peroneal studies with motor conduction velocity slow in 8%. The sural SNAP was low in 17% and sensory nerve conduction velocity slow in 25%. Using a multiple regression analysis only age at diagnosis was identified as a significant predictor of peripheral nerve dysfunction (multiple R = 0.55; p < 0.01). This study demonstrates that mild peripheral nerve dysfunction is common in patients with cystic fibrosis. With the improving long term survival of these patients we predict that the prevalence and severity of this complication will increase.

Entities:  

Mesh:

Year:  1995        PMID: 7672935     DOI: 10.1007/bf02967830

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  17 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Peripheral neuropathy in chronic disease of the respiratory tract.

Authors:  O Appenzeller; R D Parks; J MacGee
Journal:  Am J Med       Date:  1968-06       Impact factor: 4.965

3.  Peripheral neuropathy in chronic obstructive lung disease.

Authors:  N Moore; G Lerebours; J Senant; G Ozenne; P David; G Nouvet
Journal:  Lancet       Date:  1985-12-07       Impact factor: 79.321

4.  Evidence of motor neuron involvement in chronic respiratory insufficiency.

Authors:  G Valli; S Barbieri; P Sergi; Z Fayoumi; P Berardinelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

5.  Vasculitis complicating cystic fibrosis.

Authors:  M J Finnegan; J Hinchcliffe; D Russell-Jones; S Neill; E Sheffield; D Jayne; A Wise; M E Hodson
Journal:  Q J Med       Date:  1989-07

Review 6.  Cystic fibrosis. 2. Lung injury in cystic fibrosis.

Authors:  J S Elborn; D J Shale
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

Review 7.  Cystic fibrosis and malnutrition.

Authors:  H P Chase; M A Long; M H Lavin
Journal:  J Pediatr       Date:  1979-09       Impact factor: 4.406

8.  Cystic fibrosis in the United Kingdom 1977-85: an improving picture. British Paediatric Association Working Party on Cystic Fibrosis.

Authors: 
Journal:  BMJ       Date:  1988-12-17

9.  Neuropathy in chronic obstructive pulmonary disease: a multicentre electrophysiological and clinical study.

Authors:  J A Jarratt; C N Morgan; J A Twomey; R Abraham; P C Sheaff; J B Pilling; J Payan; J D Mitchell; O Tang; F Arnaud
Journal:  Eur Respir J       Date:  1992-05       Impact factor: 16.671

10.  A study of the relationship between neurological function and serum vitamin E concentrations in patients with cystic fibrosis.

Authors:  H J Willison; D P Muller; S Matthews; S Jones; A Kriss; R J Stead; M E Hodson; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

View more
  2 in total

1.  CFTR-deficient pigs display peripheral nervous system defects at birth.

Authors:  Leah R Reznikov; Qian Dong; Jeng-Haur Chen; Thomas O Moninger; Jung Min Park; Yuzhou Zhang; Jianyang Du; Michael S Hildebrand; Richard J H Smith; Christoph O Randak; David A Stoltz; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

2.  Inhibition of endocytosis suppresses the nitric oxide-dependent release of Cl- in retinal amacrine cells.

Authors:  Vernon K Dunn; Evanna Gleason
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.